Drugmakers would develop better cancer treatments for elderly populations if they included more of them in their clinical trials, the FDA said Thursday in policy recommendations to improve representation for older patients.
“Older adults are underrepresented in cancer clinical trials despite representing a growing segment of the population of cancer patients,” according to the recommendations.
